What steps did scientists take to learn the basics about ERBB activation? EGFR has been the most extensively studied with respect to activation compared with the other ERBB receptors, so our ...
Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...
However, activation of the Ras–MAPK pathway has not been as well correlated with response to EGFR inhibitors as the PI3K–Akt pathway 158. Experience with gefitinib and erlotinib has taught us ...
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...
EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...
GlobalData on MSN4mon
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trialIndividuals with metastatic or locally advanced NSCLC harbouring an EGFR-activating mutation, who had previously failed third ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback